Asper Biogene

Fountain Medical Development is a clinical contract research organization (CRO) offering a full range of ICH GCP compliant clinical research services in China, US, Japan, and Europe. FMD has extensive global experience in multiple therapeutic areas. The company has completed dozens of registrations trials which supported marketing authorization applications in US and Europe.

Our people is the basis of our success. The 1,700+ professionals are dedicated and diverse. At any given moment, at least 3 languages are spoken in our 20 offices in Asia, US, and Europe.

FMD is on the forefront of the paradigm shift in global clinical development. The regulatory reform in China has the potential to fundamentally change how an innovative therapy is developed. FMD is on the frontline building and shaping the future.

FMD is large enough to serve 7 out the 10 largest Pharma companies, and nimble enough to customize to the needs of startup firms.

In the US and Europe, FMD is doing business as FMD K&L. In China, we operate under the name FMD. Whatever the names are, the company is managed globally by a seasoned senior management team comprised of industry veterans.

Together we build a bright future.

Qualitis Ltd, is a Full-Service Clinical Research and Medical Consulting Organization based in Greece and offering a comprehensive portfolio of clinical development and medical consulting services to the Pharmaceutical, Biotechnology and Medical Device industries.

Through a commitment to a Company culture of superior quality service, integrity and innovation, Qualitis focuses on exceeding its customers particular needs and expectations.

Qualitis Team possesses an in-depth and long-term experience and expertise in both clinical research and medical-marketing environment and is strongly dedicated in constant learning and continuous improvement driven to create added value for our customers and become an integral part of their business success.

With a strong focus on people and standards, Qualitis has built upon the 3 milestones of business success: Quality, Commitment and Customer Trust.

Our specialty areas include but are not limited to the following:
-Cardiovascular diseases
-Neurology & Psychiatry
-Pulmonary/Respiratory
-Genitourinary
-Gastroenterology
-Oncology
-Orthopedics
-Pediatrics
-Biotechnology
-Allergy/Immunology
-Dermatology
-Virology
-Endocrinology
-Hematology
-Ophthalmology

Areas of Operation-Projects Portfolio:
-Phase II-IV Clinical Trials
-Medical Device Studies
-Non-Interventional Studies
-Pharmacovigilance Studies
-IIS (Investigator Initiated Studies)
-Epidemiological Studies
-Market Surveys

Customers Profile:
-Pharmaceutical Companies
-Biotechnology Companies
-Medical Devices Companies
-Academic Research Institutes & Hospitals
-International CROs

Contact Details: E-mail: info@qualitis.gr
Telephone: +30 210-7797750
Fax: +30 210-7470441

Accell Clinical Research is an international full-service Contract Research Organization (CRO) managing Phase I-III clinical trials for 10+ years across Eastern Europe. With local presence, including highly qualified medical staff and legal entities in the region, we successfully recruit patients both in EU and outside EU in post-Soviet countries (CIS). All together we provide guaranteed fast patient recruitment in 20+ countries across the region.

⬇︎ ACCELL'S SERVICES for Phase I-III clinical trials:

• Strategic guidance and trial set-up:
• Feasibility research and site selection
• Study documentation development
• Regulatory support
• Clinical supply import and management
• Selection and management of clinical study vendors
• Project management
• Clinical & medical monitoring
• Data management and biostatistics
• Quality assurance
• Safety management
• TMF/eTMF services
• Functional outsourcing of a clinical team

⬇︎ THERAPEUTIC AREAS
• Oncology
• Cardiovascular
• Immunology
• Gastroenterology
• Neurology
• Endocrinology

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company’s multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this “Data-driven R&D Autobahn to Cures” for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,700 highly qualified people. The Company’s 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence.

EastHORN is a full service CRO with operations in key locations in Western Europe and offices covering the entire European region. Experienced in Phase I to Phase IV studies across all therapeutic areas including Neurology & Psychiatry, Oncology, Cardiovascular Diseases, Infectious & Parasitic Diseases and Gastrointestinal Diseases. The large and diverse patient populations also make this region an ideal location for rare disease studies.

EastHORN has over 120 employees and a presence in virtually every European country, Established in 2004 and boasting a highly experienced management team EastHORN provides a high quality service combined with the rapid recruitment for which this region is renowned.

EastHORN’s response to the coronavirus Covid-19 crisis

Our priorities at this challenging time are the well-being of our staff and their families, and of the clinical staff and patients in our clinical trials. We are monitoring the Covid-19 pandemic situation in each of the countries in which we operate and complying with local/national directives. The vast majority of our staff are able to work from their homes and, where possible, travel has been stopped.
We are making every effort to minimize the impact on our business and our clients’ projects and our project managers are keeping their clients updated on the challenges and solutions in their respective projects. In many cases monitoring visits to clinical facilities have been suspended for the time being; these have been replaced by remote monitoring and critical data review, with non-essential activities being postponed. We want to assure our clients that we have robust business continuity plans in place, that we are adequately staffed and that we remain focused on their projects. As soon as we can be up and running normally again we will we will be doing our best to recover from this challenge.